Date: February 11, 2026 Source: Cochrane Summary: Three major reviews commissioned by the World Health Organization find that GLP-1 drugs including tirzepatide (sold as Mounjaro and Zepbound), semaglutide (Ozempic and Wegovy), and liraglutide (Victoza and Saxenda) can lead to substantial weight loss in people with obesity
We recommend you consult with us to assess if you can be a candidate for Semaglutide GLP-1 therapy for weight loss
Related articles How can we help
Williams: If I remember the episode correctly, it turns out we miss about half of thyroid nodules on physical examination, even when they are over a centimeter
A controlled clinical trial revealed that patients with GLP-1ARs therapy showed significant reductions in perception of all five basic tastes, scoring 29% lower on standardized tests like the Waterless Empirical Taste Test (WETT ) compared to controls
The safety profile of exenatide and other GLP-1 receptor agonists has been extensively evaluated through clinical trials and post-marketing surveillance